The FDA just approved Epidiolex, the GW Pharma seizure drug derived from cannabis, giving children with two rare and serious forms of epilepsy a new treatment—and companies looking to develop marijuana-based drugs a model for their own path to market.
read moreMore than two years ago, Pfizer’s Ibrance won an FDA nod to treat some breast cancer patients whose disease progressed after endocrine therapy. But new study results suggest the drug may not actually help those patients live longer. More: In
read moreIn a new post-hoc analysis of Jardiance’s CV outcomes test, investigators found that the drug reduced kidney disease progression. More: ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis Source: fierce
read moreTagrisso’s recent approvals in first-line lung cancer have AstraZeneca management optimistic about the $3 billion sales target it set years ago. But some analysts have higher hopes—and one just came up with a far more bullish estimate. More: Forget Tagrisso's
read moreSo far, Roche’s Tecentriq hasn’t been able to find a piece of the lung cancer market to call its own. But that may change after its latest trial win. More: With latest data, has Roche's Tecentriq found a blockbuster lung
read morePharmaTimes Media has announced an important new partnership with Bowel Cancer UK and Beating Bowel Cancer ahead of its 2018 Communications Team of the Year competition. More: PharmaTimes Media teams up with leading bowel cancer charity Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals